Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dova Pharmaceuticals Inc (DOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 648,600
  • Shares Outstanding, K 28,200
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,960 K
  • 36-Month Beta -0.31
  • Price/Sales 144.32
  • Price/Cash Flow N/A
  • Price/Book 5.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.83
  • Number of Estimates 3
  • High Estimate -0.80
  • Low Estimate -0.89
  • Prior Year -0.38
  • Growth Rate Est. (year over year) -118.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.65 +13.51%
on 08/10/18
25.13 -6.73%
on 07/23/18
-0.42 (-1.76%)
since 07/17/18
3-Month
20.65 +13.51%
on 08/10/18
35.33 -33.65%
on 06/26/18
-3.21 (-12.05%)
since 05/17/18
52-Week
20.65 +13.51%
on 08/10/18
37.00 -36.65%
on 02/20/18
-2.19 (-8.54%)
since 08/17/17

Most Recent Stories

More News
Dova Pharmaceuticals Reports Second Quarter 2018 Operating and Financial Results

DOPTELET approved by FDA on May 21, 2018

DOVA : 23.44 (+1.91%)
Dova Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 9, 2018

Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) will host a conference call on Thursday, August 9, 2018 at 4:30 p.m. ET to discuss second quarter 2018 financial results and recent operational highlights. A question-and-answer...

DOVA : 23.44 (+1.91%)
Nancy J. Wysenski Joins Dova Pharmaceuticals' Board of Directors

Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Nancy J. Wysenski will join Dova's Board of Directors effective immediately. In addition to her board responsibilities, Ms. Wysenki will also...

DOVA : 23.44 (+1.91%)
Dova Pharmaceuticals Announces Publication of Pivotal Phase 3 Data and Upcoming Congress Presentations for DOPTELET(R) (avatrombopag)

Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the recent online publication of its pivotal Phase 3 trial data on the use of DOPTELET(R) (avatrombopag) for the treatment of thrombocytopenia...

DOVA : 23.44 (+1.91%)
Dova Pharmaceuticals Announces Availability of DOPTELET(R) in the United States

Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the availability of DOPTELET in the United States for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are...

DOVA : 23.44 (+1.91%)
Dova Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference

Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Jefferies 2018 Global Healthcare Conference on Tuesday,...

DOVA : 23.44 (+1.91%)
Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET(R) (avatrombopag)

Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the U.S. Food and Drug Administration (FDA) has completed their Priority Review and approved DOPTELET (avatrombopag) for the treatment of thrombocytopenia...

DOVA : 23.44 (+1.91%)
Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results

PDUFA date for avatrombopag of May 21, 2018

DOVA : 23.44 (+1.91%)
Dova Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 9, 2018

Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) will host a conference call on Wednesday, May 9, 2018 at 4:30 p.m. ET to discuss first quarter 2018 financial results and recent operational highlights. A question-and-answer...

DOVA : 23.44 (+1.91%)
Investor Expectations to Drive Momentum within Horizon Bancorp (IN), Allegiant Travel, Littelfuse, Dova Pharmaceuticals, BOK Financial, and Northfield -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Horizon Bancorp (IN) (NASDAQ:HBNC),...

NFBK : 16.54 (+0.12%)
ALGT : 135.70 (unch)
DOVA : 23.44 (+1.91%)
BOKF : 99.78 (+0.35%)
LFUS : 219.09 (+0.02%)
HBNC : 20.83 (-0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade DOVA with:

Business Summary

Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company's drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 24.06
1st Resistance Point 23.75
Last Price 23.44
1st Support Level 22.88
2nd Support Level 22.32

See More

52-Week High 37.00
Fibonacci 61.8% 30.75
Fibonacci 50% 28.83
Fibonacci 38.2% 26.90
Last Price 23.44
52-Week Low 20.65

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar